Danaher Supports Boao Lecheng Pilot Zone in Achieving 'Three Synchronizations' of Medical Technology, Equipment, and Pharmaceuticals

Boao, Hainan, April 14, 2021 /PRNewswire/ -- On April 13, the "Never-Ending" International Pharmaceutical and Medical Device Exhibition, hosted by the Administration Bureau of Boao Lecheng International Medical Tourism Pilot Zone (hereinafter referred to as the Lecheng Pilot Zone), was grandly held in Boao. As the only exhibition in China authorized to showcase international innovative pharmaceuticals and medical devices not yet launched in the Chinese market, it serves as a key showcase window and platform for the Lecheng Pilot Zone's substantial achievement of "triple synchronization" with global advances in pharmaceuticals, equipment, and technologies. The inaugural edition held last year was a resounding success, and this year's second edition attracted numerous global leaders in innovative pharmaceuticals and medical devices, including Danaher Corporation.

Meanwhile, at the “Boao Lecheng 2020 Annual Conference on Summary of International Innovative Drugs and Medical Devices Work” held on April 12, a number of pharmaceutical and medical device companies, healthcare institutions, and expert teams were recognized and commended. For achieving international parity in the introduction and implementation of specially approved drugs and medical devices in Lecheng, Danaher was awarded the “Contribution Award for the Introduction of International Innovative Drugs and Medical Devices” by the Lecheng Pilot Zone.

Danaher Receives the “Award for Contributions to the Introduction of International Innovative Drugs and Medical Devices” from the Boao Lecheng International Medical Tourism Pilot Zone

Danaher Showcases a Lineup of Premier Innovative Products from Its Healthcare Subsidiaries

At this grand event, Danaher showcased a wide array of top-tier innovative products from its healthcare operating companies, covering multiple fields including hematology analysis, molecular diagnostics, critical care testing, pathological diagnosis, breast vacuum-assisted biopsy, hospital filtration, clinical mass spectrometry, surgical microscopy, and flow cytometry. Among these, a total of 10 innovative products were exhibited in China for the first time and were included in the "Global Innovative Products List for the Pharmaceutical and Medical Device Exhibition" released on the same day, demonstrating Danaher's globally leading technological innovation capabilities.

For instance, Beckman Coulter Clinical Diagnostics’ DxH 900 Hematology Analyzer achieved global installations exceeding 300 units shortly after its launch. Amid the global COVID-19 pandemic, the early sepsis indicators accompanying the DxH 900 were the only parameters with early sepsis alert functionality included in complete blood count (CBC) reports to receive both U.S. FDA clearance and CE marking. These indicators can signal potential sepsis and guide antibiotic usage. Additionally, the DxA5000 Fit Automated Sample Processing System features an innovative pre-analytical sample quality assessment function that evaluates each specimen within three seconds. This capability enables multi-parameter screening of every specimen during the pre-analytical phase, thereby significantly reducing the risk of errors in the laboratory.

Cepheid’s SARS-CoV-2/Flu A/Flu B/RSV Combo Assay can rapidly detect and differentiate SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus in approximately 36 minutes;

Pall water filters can play a key role in hospital water safety management systems that are vulnerable to contamination and infection by particulates and microorganisms;

SCIEX’s Citrine LC-MS/MS detection system enables accurate quantification of target compounds in complex matrices, and is indispensable for therapeutic drug and metabolite monitoring, including the detection of trace endogenous biomarkers such as proteins or peptides, as well as for the discovery and validation of novel biomarkers.

Beckman Coulter Life Sciences’ AQUIOS CL fully automated flow cytometer employs Load & Go technology to directly analyze samples from collection tubes, eliminating the need for sample preparation. This enhances productivity and improves biosafety by minimizing operator contact with specimens. Additionally, its other innovative product, the ClearLLab 10-Color Detection System, utilizes a standardized laboratory protocol for leukemia and lymphoma immunophenotyping, simplifying workflows through 10-color analysis.

“Mammotome Ruiyan” Bidirectional Vacuum-Assisted Breast Biopsy System is specifically designed for minimally invasive rotational excision of benign breast lesions. It enables independent differentiation of multiple masses, clear traceability of each lesion, and precise tissue resection, thereby reducing overtreatment and residual lesions. With twice the excision efficiency, it significantly shortens surgical time. Recently, the product was used in the world’s first successful surgery in the Boao Lecheng International Medical Tourism Pilot Zone, marking it as the first Danaher China product to be implemented under the pilot zone’s “trial-first” policy.

Danaher Showcases a Range of Top-Tier Innovative Products from Its Healthcare Operating Companies at the Boao Lecheng “Never-Ending” International Pharmaceutical and Medical Device Exhibition

Danaher Showcases a Range of Top-Tier Innovative Products from Its Healthcare Subsidiaries at the Boao Lecheng “Never-Ending” International Pharmaceutical and Medical Device Exhibition

Danaher Helps Boao Lecheng Pilot Zone Achieve International Standards“Three Synchronizations”

As early as November 2020, Danaher forged an “enduring partnership” with Boao Lecheng, the host location of the exhibition. At that time, Danaher signed a memorandum of cooperation with the Administrative Bureau of the Boao Lecheng Pilot Zone, reaching agreements on multiple fronts, including the introduction of Danaher’s world-leading products and joint efforts to enhance the research and management capabilities of scientific institutions. Both parties expressed their hope that the signing of the memorandum would facilitate breakthrough progress in establishing the Lecheng Pilot Zone as a specialized, technologically advanced clinical medical center and a base for the research, development, and translation of cutting-edge medical technologies. This collaboration aims to leverage Danaher’s advanced technological innovation capabilities and its extensive portfolio of applied medical science and technology achievements, thereby helping the Boao Lecheng International Medical Tourism Pilot Zone fully achieve “triple synchronization” with international advanced standards in medical technologies, equipment, and pharmaceuticals.

Chunyan Wei, Vice President of Government Affairs for Danaher China, stated that by participating in the Boao Lecheng Phase II “Never-Ending” International Pharmaceutical and Medical Device Exhibition with a portfolio of innovative products and providing multi-field healthcare solutions, Danaher is actively responding to the Chinese government’s initiative to leverage Lecheng’s existing clinical and special pharmaceutical and medical device policies. This effort aims to introduce more innovative products into the Lecheng Pilot Zone, facilitate real-world data research, accelerate the clinical application of cutting-edge global pharmaceuticals and medical devices, expedite their market approval process in China, and enable more patients to benefit from the “pilot and trial” policy advantages of the Lecheng Pilot Zone.